AltruBio Inc.

Cómo llegar Página web

AltruBio Inc. AltruBio develops first-in-class immune-modulators targeting diseases of immunology and inflammation.

Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients

🎯“Driven by Purpose”—the theme of BIO 2026—captures the foundation of our work at AltruBio: advancing innovative therapi...
02/07/2026

🎯“Driven by Purpose”—the theme of BIO 2026—captures the foundation of our work at AltruBio: advancing innovative therapies that have the potential to meaningfully improve patients’ lives while creating long-term value for stakeholders.

Our momentum continues to build, supported by encouraging Phase 2a clinical results – a differentiated scientific approach – and the steadfast confidence of our investors, partners, and collaborators.

AltruBio’s President & CEO Dr. Judy Chou and Edwin Powers, VP & Head of Finance and Corporate Development, left BIO energized by the high-quality conversations, strategic partnerships, and growing interest in our pipeline. These engagements reinforce the significant opportunity ahead as we advance ALTB-268 into the ASCEND-UC Phase 2b study.

With a strong clinical foundation and a clear development strategy, we remain focused on unlocking the full potential of ALTB-268 and expanding our impact in immunological and inflammatory diseases. We are excited about the next phase of growth and look forward to delivering meaningful outcomes for patients, partners, and stakeholders alike.

🎯「Driven by Purpose (使命驅動，創新前行）」

這不僅是今年 BIO 2026（北美生物科技產業展）的大會主題，更是 AltruBio 一路以來堅持的核心理念！我們致力於開發創新的免疫療法，期望在改善患者生活品質的同時，也為合作夥伴及投資人創造長遠價值。

AltruBio 持續穩健向前，憑藉令人鼓舞的 Phase 2a 臨床試驗成果、獨樹一幟的科學機制，以及來自投資人、合作夥伴與各界持續的支持與信任，我們正準備迎向下一個重要里程碑。

日前圓滿落幕的 BIO 2026 大會中上，AltruBio總裁暨執行長周慧泉博士 (Judy Chou, Ph.D.) 與財務暨企業發展副總裁 Edwin Powers滿載而歸，與全球業界夥伴進行了許多高品質且富有建設性的交流，並就策略合作及未來發展展開深入討論。生技醫藥界對AltruBio產品線日益增長的高度關注，也更加堅定了我們推進 ALTB-268 進入全球Phase 2b 「ASCEND-UC」潰瘍性結腸炎臨床試驗的信心。

展望未來，我們將持續以堅實的臨床基礎與明確的研發策略，全力推動 ALTB-268 的臨床開發，並拓展其在免疫與發炎性疾病領域的應用潛力。我們對下一階段成長充滿信心，期待能為患者、合作夥伴及投資人創造更具意義的成果。

#全心醫藥 #北美生物科技產業展 #生技大會 #生技創新

🎊Exciting progress at AltruBio – Our President & CEO, Dr. Judy Chou, recently spoke with Biotech TV at BIO 2026, highlig...
29/06/2026

🎊Exciting progress at AltruBio –

Our President & CEO, Dr. Judy Chou, recently spoke with Biotech TV at BIO 2026, highlighting the company’s continued clinical momentum and growth strategy.

Dr. Chou discussed AltruBio’s encouraging Phase 2a results and the advancement of our lead program into the global Phase 2b ASCEND-UC study in ulcerative colitis—an important milestone that underscores the potential of our differentiated immune-modulating approach.

She also shared how AltruBio is actively exploring strategic partnerships to expand our platform across additional immunological and inflammatory indications, positioning the company for long-term value creation.

Watch the full interview via the link in comment.👇

🎊AltruBio 持續邁向新里程碑！

AltruBio總裁暨執行長周慧泉博士，近日於BIO 2026（北美生物科技產業展）大會期間接受 Biotech TV 專訪，分享公司最新的臨床進展與未來發展策略。

在訪談中，周總裁特別提到AltruBio鼓舞人心的 Phase 2a 臨床試驗結果，以及公司核心產品正式推進至全球 Phase 2b 「ASCEND-UC」潰瘍性結腸炎臨床試驗。這項重要里程碑再次印證AltruBio差異化免疫調節療法的發展潛力。

此外，她也分享了AltruBio持續積極尋求策略合作夥伴，期望將公司的技術平台拓展至更多免疫及發炎性疾病相關的適應症，為公司創造長期的核心價值。

歡迎點擊留言區的連結，觀看完整專訪！👇

#2026北美生技展 #全心醫藥 #周慧泉

AltruBio is at BIO 2026!AltruBio’s President & CEO, Dr. Judy Chou, and VP of Finance & Corporate Development, Edwin Powe...
20/06/2026

AltruBio is at BIO 2026!

AltruBio’s President & CEO, Dr. Judy Chou, and VP of Finance & Corporate Development, Edwin Powers, look forward to connecting with potential partners and industry leaders at BIO International Convention 2026, June 22–25 in San Diego.

We are enthusiastic about building strategic partnerships to accelerate innovation in ulcerative colitis (UC) and facilitate indication expansion for immunological and inflammatory diseases.

AltruBio 期待與您在 BIO 2026 相會！

AltruBio總裁暨執行長周慧泉博士與財務暨企業發展副總裁Edwin Powers，將於 2026 年 6 月 22 日至 25 日參加在美國聖地牙哥舉行的 BIO International Convention 2026（北美生物科技產業展），期待與全球生技產業合作夥伴及產業領袖交流會面。

我們持續積極尋求策略性合作夥伴關係，以便共同加速潰瘍性結腸炎（Ulcerative Colitis, UC）領域的創新發展，並推動免疫及發炎性疾病相關適應症的拓展。

#全心醫藥 #2026北美生技展 #周慧泉

At AltruBio, our mission has always been driven by a simple but powerful belief: scientific innovation should lead to me...
11/06/2026

At AltruBio, our mission has always been driven by a simple but powerful belief: scientific innovation should lead to meaningful improvements in patients’ lives. Please see the post from our President and CEO, Dr. Judy Chou , following this Podcast interview:

“I’m pleased to finally share Episode 4 of my conversation on the Biotech Startups Podcast with Jon Chee — a discussion that focuses on the origin story, mission, challenges, and vision behind AltruBio Inc..

This episode is especially meaningful to me because it goes beyond career milestones and dives into why I decided to leave a global leadership role in big pharma to take on the risk of becoming a biotech CEO. We discussed how a group of former Genentech executives came together around a shared belief that there was still significant unmet need in autoimmune diseases, and how that conviction became the foundation of AltruBio Inc..

In this episode, we talk about:

🔹 The journey from Bayer to AltruBio Inc. and the decision to pursue a patient-centric biotech mission

🔹 Why the PSGL-1 immune checkpoint pathway captured our attention as a potentially transformative approach in immunology

🔹 Building AltruBio with an experienced, highly collaborative team united by a common vision

🔹 Navigating near-bankruptcy, fundraising challenges, and the 30-day sprint that ultimately led to Series A and Series B financing

🔹 Our commitment to developing therapies that not only address disease biology but also improve the daily lives of patients living with ulcerative colitis and other immune-mediated diseases

One message that remains central to our work is that innovation should never stop at scientific novelty. It must translate into meaningful impact for patients. As we continue advancing our programs, I remain grateful to our team, investors, collaborators, and patients who make this journey possible.”

在 AltruBio，我們始終秉持一個簡單卻堅定的信念：科學創新最終必須轉化為對患者生活的實質改善。以下是我們總裁暨執行長 周慧泉博士在這集Podcast訪談後的分享與感想：

「很高興與大家分享我在Biotech Startups Podcast與Jon Chee對談的第四集節目。本集內容聚焦於AltruBio的創立歷程、企業使命、挑戰，以及未來願景。

這集訪談對我而言格外具有意義，因為它不只是回顧職涯的重要里程碑，更深入探討了我為何選擇離開大型跨國藥廠的全球領導職位，承擔風險投入生技創業之路。我們也分享了一群來自Genentech 的前高階主管，如何因共同相信自體免疫疾病領域仍存在大量未被滿足的醫療需求而凝聚在一起，並以此信念創立AltruBio。

在本集節目中，我們討論了：

🔹從Bayer到AltruBio的職涯轉折，以及投入以患者為核心的新創生技使命的決定

🔹為何PSGL-1免疫檢查點路徑吸引了我們的關注，並成為免疫學領域具有潛力的創新治療方向

🔹如何建立一支經驗豐富、高度協作，並以共同願景為目標的團隊

🔹公司曾面臨的資金困境、募資挑戰，以及最終在30天內完成關鍵募資、成功推進A輪與B輪募資的歷程

🔹我們對於開發創新療法的承諾，不僅著眼於疾病機制本身，更希望改善潰瘍性結腸炎及其他免疫介導疾病患者的日常生活

有一個核心理念始終引領我們前進：創新不應止於科學上的突破，更必須為患者帶來真正有意義的改變。隨著公司持續推進各項研發計畫，我也由衷感謝所有團隊成員、投資人、合作夥伴以及患者的支持，因為有你們的信任與投入，這段旅程才得以持續向前。」

#全心醫藥

Dirección

455 Market Street, Suite 1810
San Francisco
CA94105

Página web

,

Notificaciones

Sea el primero en enterarse: le enviaremos un correo electrónico cuando AltruBio Inc. publique novedades y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin y puede darse de baja en cualquier momento.

Atajos

Compartir

Categoría